France's LFB Biotechnologies will pay Thallion Pharmaceuticals an estimated $134 million in a development and marketing deal for Shigamabs, a drug designed to treat Shiga toxin-producing E. coli infection. The Canadian biotech company plans to conduct a Phase II trial of the product in South America in the fourth quarter.

Full Story:

Related Summaries